Catalent To Present at INTERPHEX - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Catalent To Present at INTERPHEX



Catalent will recognize 80 years of softgel advancements at INTERPHEX on March 18-20, 2014 in New York City with presentations from its senior management team, as well as graduates from the company’s Global Operations Leadership Development (GOLD) program.

On Wednesday, March 19, Sridhar Krishnan, Catalent’s vice president, Global Operations, will present “Catalent GOLD - Accelerating Leadership Pipeline in Pharma & Biotech.” Catalent’s GOLD program is a two-year leadership development opportunity, designed for university graduates who have a desire to accelerate their career growth in an entrepreneurial, fast-paced environment. Krishnan’s presentation, which takes place from 10:30 to 11:30 AM, will outline the GOLD leadership model and feature the experiences of three graduates who have participated in the program.

Also on Wednesday 19, from 2:45 to 3:45 PM, Akan Oton, director, Global Licensing & CorporateAlliances, will lead a discussion on “Commercializing Emerging Drug Delivery Technologies.” His presentation will address the evolving role of drug delivery in pharma products from a commercial perspective and will look at current trends in drug delivery and unmet needs currently being pursued. He will also give examples of a typical path to commercialization of drug delivery technologies by innovators.

On Thursday, March 20, from 11:45 AM to 12:45 PM, Bill Hartzel, director, Strategic Execution, Advanced Delivery Technologies will present, “Advanced Aseptic Processing to Reduce Risk with Sterile Fill/Finish.” His presentation will feature ways to identify the QbD elements of Blow/Fill/Seal equipment and the evaluation of the risk mitigation properties of advanced aseptic properties as well astaking a look at Catalent’s newly launched ADVASEPT technology.

Source: Catalent

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here